Testosterone undecylenate

Testosterone undecylenate
Clinical data
Trade names	Durasteron, Triolandren (mixtures)
Other names	TUe; Testosterone undecenoate; 17β-Hydroxyandrost-4-en-3-one 17β-(undec-10-enoate)
Routes of; administration	Intramuscular injection
Drug class	Androgen; Anabolic steroid; Androgen ester
Identifiers
	IUPAC name [(8R,9S,10R,13S,14S,17S)-10,13-dimethyl-3-oxo-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl] undec-10-enoate;
CAS Number	29430-26-0 ;
PubChem CID	9846790;
ChemSpider	21229627;
UNII	KU65V22IOU;
CompTox Dashboard (EPA)	DTXSID10951953 ;
ECHA InfoCard	100.045.099
Chemical and physical data
Formula	C30H46O3
Molar mass	454.695 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2OC(=O)CCCCCCCCC=C)CCC4=CC(=O)CC[C@]34C;
	InChI InChI=1S/C30H46O3/c1-4-5-6-7-8-9-10-11-12-28(32)33-27-16-15-25-24-14-13-22-21-23(31)17-19-29(22,2)26(24)18-20-30(25,27)3/h4,21,24-27H,1,5-20H2,2-3H3/t24-,25-,26-,27-,29-,30-/m0/s1; Key:PBFYIQCFOZXSKC-CNQKSJKFSA-N;

The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

Testosterone undecylenate (TUe) is an androgen/anabolic steroid medication and androgen ester which is no longer marketed.^[1]^[2]^[3] It was a component of Durasteron and Triolandren, long-acting mixtures of testosterone esters in oil solution that were administered by intramuscular injection.^[4]^[5]^[6]^[7]

References

^ Shapiro S, Weinburg K, Freedman L (1956). "Notes - Long-Acting Androgens". The Journal of Organic Chemistry. 21 (11): 1300–1302. doi:10.1021/jo01117a602. ISSN 0022-3263.
^ Gould D, Finckenor L, Hershberg EB, Cassidy J, Perlman PL (1957). "Long-acting Testosterone Esters. Some Considerations on their Biological Utilization1". Journal of the American Chemical Society. 79 (16): 4472–4475. doi:10.1021/ja01573a061. ISSN 0002-7863.
^ US 2855341, Meier, R; Wettstein, A & Lang, E, "Testosterone compositions", published 1958-10-07, assigned to Ciba pharmaceutical Products, Inc.
^ Schuermann H, Doepfmer R (1960). Fertilitätsstörungen beim Manne. Springer-Verlag. pp. 260–. ISBN 978-3-642-94784-1.
^ Ufer J (1960). Hormontherapie in der Frauenheilkunde: Grundlagen und Praxis. Gruyter. p. 153. ISBN 9783111138770.
^ Aakvaag A, Vogt JH (March 1969). "Plasma testosterone values in different forms of testosterone treatment". Acta Endocrinologica. 60 (3): 537–542. doi:10.1530/acta.0.0600537. PMID 5395873. Triolandren®, for intramuscular use, kindly supplied by Ciba, Basel, through Kobro 8c Co., Oslo, containing three different testosterone esters, in the following amounts of testosterone equivalents per ml oil: propionate 20 mg; valerate 80 mg; undecylenate 150 mg.
^ Zachmann M, Prader A (January 1970). "Anabolic and androgenic effect of testosterone in sexually immature boys and its dependency on growth hormone". The Journal of Clinical Endocrinology and Metabolism. 30 (1): 85–95. doi:10.1210/jcem-30-1-85. PMID 4311616. Triolandren, CIBA; 250 mg of this preparation contains 20 mg of testosterone propionate, 80 mg of testosterone-n-valerianate, and 150 mg of testosterone undecylenate—250 mg thus contains 173.8 mg of testosterone; the remaining 76.2 mg consists of the ester components [...]

This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it.

[ShapiroWeinburg1956-1] Shapiro S, Weinburg K, Freedman L (1956). "Notes - Long-Acting Androgens". The Journal of Organic Chemistry. 21 (11): 1300–1302. doi:10.1021/jo01117a602. ISSN 0022-3263.

[GouldFinckenor1957-2] Gould D, Finckenor L, Hershberg EB, Cassidy J, Perlman PL (1957). "Long-acting Testosterone Esters. Some Considerations on their Biological Utilization1". Journal of the American Chemical Society. 79 (16): 4472–4475. doi:10.1021/ja01573a061. ISSN 0002-7863.

[US2855341A-3] US 2855341, Meier, R; Wettstein, A & Lang, E, "Testosterone compositions", published 1958-10-07, assigned to Ciba pharmaceutical Products, Inc.

[SchuermannDoepfmer1960-4] Schuermann H, Doepfmer R (1960). Fertilitätsstörungen beim Manne. Springer-Verlag. pp. 260–. ISBN 978-3-642-94784-1.

[Ufer1960-5] Ufer J (1960). Hormontherapie in der Frauenheilkunde: Grundlagen und Praxis. Gruyter. p. 153. ISBN 9783111138770.

[pmid5395873-6] Aakvaag A, Vogt JH (March 1969). "Plasma testosterone values in different forms of testosterone treatment". Acta Endocrinologica. 60 (3): 537–542. doi:10.1530/acta.0.0600537. PMID 5395873. Triolandren®, for intramuscular use, kindly supplied by Ciba, Basel, through Kobro 8c Co., Oslo, containing three different testosterone esters, in the following amounts of testosterone equivalents per ml oil: propionate 20 mg; valerate 80 mg; undecylenate 150 mg.

[ZachmannPrader1970-7] Zachmann M, Prader A (January 1970). "Anabolic and androgenic effect of testosterone in sexually immature boys and its dependency on growth hormone". The Journal of Clinical Endocrinology and Metabolism. 30 (1): 85–95. doi:10.1210/jcem-30-1-85. PMID 4311616. Triolandren, CIBA; 250 mg of this preparation contains 20 mg of testosterone propionate, 80 mg of testosterone-n-valerianate, and 150 mg of testosterone undecylenate—250 mg thus contains 173.8 mg of testosterone; the remaining 76.2 mg consists of the ester components [...]

[1]

See also

References